Jump Financial, LLC Denali Therapeutics Inc. Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 21, 2024	SELL	$20.63 - $30.17 $1.52 Million - $2.22 Million	-73,584 Reduced 78.81%	19,787 $408,000
Q3 2023 Nov 07, 2023	BUY	$20.63 - $30.17 $408,205 - $596,973	19,787 New	19,787 $408,000
Q1 2023 Oct 21, 2024	BUY	$21.91 - $32.67 $2.05 Million - $3.05 Million	93,371 New	93,371 $2.15 Million
Q1 2023 May 03, 2023	BUY	$21.91 - $32.67 $2.05 Million - $3.05 Million	93,371 New	93,371 $2.15 Million
Q3 2022 Nov 07, 2022	BUY	$25.97 - $38.53 $2.28 Million - $3.39 Million	87,855 Added 614.5%	102,152 $3.14 Million
Q2 2022 Aug 09, 2022	BUY	$20.88 - $35.19 $298,521 - $503,111	14,297 New	14,297 $420,000
Q1 2022 May 12, 2022	SELL	$29.0 - $47.27 $295,887 - $482,295	-10,203 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$42.59 - $55.02 $434,545 - $561,369	10,203 New	10,203 $455,000
Q2 2021 Aug 13, 2021	SELL	$50.3 - $78.44 $719,290 - $1.12 Million	-14,300 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $597,180 - $904,983	11,100 Added 346.88%	14,300 $817,000
Q4 2020 Feb 12, 2021	BUY	$36.89 - $93.56 $118,048 - $299,392	3,200 New	3,200 $268,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.